Beta Bionics Earns Buy Ratings and $25 Price Target from Stifel
Stifel initiates Beta Bionics (BBNX) coverage with a Buy rating and $25 price target, highlighting the iLet’s potential in the underserved automated insulin delivery market. Analysts praise the system’s ease of use and advanced features, predicting significant market disruption and improved diabetes management.
Beta Bionics Earns Buy Ratings and $25 Price Target from Stifel Read More »